Connect
MJA
MJA

Stroke care in Australia: why is it still the poor cousin of health care?

Tammy C Hoffmann and Richard I Lindley
Med J Aust 2013; 199 (3): . || doi: 10.5694/mja13.10551
Published online: 5 August 2013

In reply: In response to Macdonald’s letter, we agree there are many effective interventions for stroke that should be routinely available, including stroke units and early coordinated care for minor strokes and transient ischaemic attacks (early care is particularly neglected in Australia). However, thrombolysis is one of the interventions that should be more widely available. Australian and international guidelines (the National Health and Medical Research Council [NHMRC]-approved clinical guidelines for stroke management, the United Kingdom Royal College of Physicians stroke guidelines and the American Heart Association/American Stroke Association guidelines) recommend thrombolysis with alteplase for acute ischaemic stroke.1-3 While there is a risk of early death from intracranial haemorrhage, long-term outcomes are significantly improved with thrombolysis. Although the primary outcome of the third international stroke trial (IST-3) was not significant, there was a significant improvement in 6-month disability (a prespecified secondary outcome) in the alteplase group, and no difference in number of deaths by 6 months (as the alteplase group had a lower death rate from 7 days to 6 months).4 It is on the basis of all of this evidence, confirming that treatment is beneficial, that guidelines consistently recommend thrombolysis as the standard of care for those who are eligible.


  • 1 Centre for Research in Evidence-Based Practice, Bond University, Gold Coast, QLD.
  • 2 School of Health and Rehabilitation Sciences, University of Queensland, Brisbane, QLD.
  • 3 University of Sydney, Sydney, NSW.
  • 4 George Institute for Global Health, Sydney, NSW.


Correspondence: thoffman@bond.edu.au

Competing interests:

Tammy Hoffmann is a member of the National Stroke Foundation Clinical Council, but does not receive payment for this involvement. Richard Lindley is Chair of the Clinical Council and Board Member for the National Stroke Foundation, but does not receive payment for these positions.

  • 1. National Stroke Foundation. Clinical guidelines for stroke management 2010. http://strokefoundation.com.au/health-professionals/tools-and-resources/clinical-guidelines-for-stroke-prevention-and-management (accessed Apr 2013).
  • 2. Royal College of Physicians Intercollegiate Stroke Working Party. National clinical guideline for stroke. 4th ed. London: RCP, 2012. http://www.rcplondon.ac.uk/publications/national-clinical-guidelines-stroke (accessed Apr 2013).
  • 3. Jauch EC, Saver JL, Adams HP Jr, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013; 44: 870-947.
  • 4. Wardlaw JM, Murray V, Berge E, et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet 2012; 379: 2364-2372.
  • 5. Sandercock P, Wardlaw JM, Lindley RI, et al; IST-3 collaborative group. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet 2012; 379: 2352-2363.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.